Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004

BJU Int. 2008 Mar;101(5):547-55. doi: 10.1111/j.1464-410X.2007.07338.x. Epub 2008 Jan 10.

Abstract

Objective: To aid the interpretation of the trends in prostate cancer mortality, which declined in the UK in the early 1990 s for unknown reasons, by investigating prostate cancer death rates, incidence and treatments in England and Wales in 1975-2004.

Methods: Join-point regression was used to assess secular trends in mortality and incidence (source: Office of National Statistics), radical prostatectomy and orchidectomy (source: Hospital Episode Statistics database) and androgen-suppression drugs (source: Intercontinental Medical Statistics).

Results: Prostate cancer mortality declined from 1992 (95% confidence interval, CI, 1990-94). The relative decline in mortality to 2004 was greater and more sustained amongst men aged 55-74 years (annual percentage mortality reduction 2.75%; 95% CI 2.33-3.18%) than amongst those aged >or=75 years (0.71%, 0.26-1.15%). The use of radical prostatectomy increased between 1991 (89 operations) and 2004 (2788) amongst men aged 55-74 years. The prescribing of androgen suppression increased between 1987 (33,000 prescriptions) and 2004 (470,000).

Conclusions: The decrease in prostate cancer mortality was greater amongst men aged 55-74 years than in those aged >or=75 years, but pre-dated the substantial use of prostate-specific antigen screening and radical prostatectomy in the UK. An increase in radical therapy amongst younger groups with localized cancers and screen-detected low-volume locally advanced disease as a result of stage migration, as well as prolonged survival from increased medical androgen suppression therapy, might partly explain recent trends.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • England / epidemiology
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Mortality / trends
  • Prostate-Specific Antigen / blood
  • Prostatectomy / statistics & numerical data*
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / therapy
  • Regression Analysis
  • Wales / epidemiology

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Prostate-Specific Antigen